Bluebook
Pharma Services: Drug Development July 2024
2024 - July: Report on M&A and financing activity in the pharma services drug development industry for CEOs and private equity professionals
Crosstree BlueBooks provide an executive review of key health sciences transactions, financial movements, and public market activity. BlueBooks also offer a glimpse of how valuations are changing and how recent trends may affect future transactions.
Highlights from this edition:
- BridgeView Life Sciences was acquired by Zensar Technologies
- Exima Research Network, LLC announced its acquisition of Tidewater Clinical Research, Inc.
- Huma Therapeutics closed a $80MM Series A Financing, led by AstraZenca PLC (LSE:AZN), HAT SGR SpA, Leaps by Bayer, Hitachi Ventures GmbH